AbbVie’s and Neurocrine Biosciences’ treatment for uterine fibroids successfully completes phase III trial

AbbVie and Neurocrine Biosciences announced that the second positive phase III trial was successful for their uterine fibroids drug elagolix, enabling another regulatory filing for the drug. Both companies are currently waiting for an FDA verdict in the US in the coming weeks on elagolix as a treatment for endometriosis-related pain, although uterine fibroids are

Continue Reading

FDA Grants Bristol-Myers Squibb & AbbVie’s Elotuzumab Breakthrough Status

US regulatory body, the Food and Drug Administration (FDA), have granted breakthrough therapy status to Bristol-Myers Squibb and AbbVie’s elotuzumab to treat multiple myeloma (MM). The designation has been granted by the FDA for elotuzumab’s use with lenalidomide and dexamethasone in patients who have previously received one or more therapies to treat multiple myeloma. Elotuzumab

Continue Reading